Expansion into diabetes treatment through a Japanese commercialization partnership for Mounjaro
First written in FY2023-Q2. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「Eli Lilly Japan K.K. obtained Japanese marketing approval in December 2024 for Zepbound®, a long-acting GIP/GLP-1 receptor agonist, for the indication of obesity, and began sales in April 2025. As with Mounjaro®, the same molecule marketed in Japan by both companies as a treatment for type 2 diabetes, 田辺三菱製薬 will distribute and sell Zepbound® in Japan, while Eli Lilly Japan K.K. and 田辺三菱製薬 will jointly provide information on the product.」
Following Mounjaro, the approval and launch in Japan of Zepbound, an obesity treatment based on the same molecule, and the two companies' distribution, sales and information-provision arrangements were specified. - FY2025-H1AdvancedAnnual report
「In pharmaceuticals, both revenue and core operating profit increased despite the impact of drug price revisions and other factors on domestic prescription drugs, due to growth in RADICAVA ORS®, a treatment for amyotrophic lateral sclerosis (ALS) launched in the United States, and foreign exchange effects; growth in Mounjaro, a long-acting GIP/GLP-1 receptor agonist, and influenza vaccines; and the smooth launch of Govic® aqueous suspension for injection, a combined adsorbed, purified pertussis, diphtheria, tetanus, inactivated polio and Haemophilus influenzae type b vaccine.」
For the Pharma business, including the Japanese commercialization partnership for Mounjaro, growth in Mounjaro sales was identified as a factor contributing to increases in revenue and core operating profit during the interim period. - FY2023RestatedAnnual report
「In July 2022, we entered into a Japanese commercialization partnership agreement with Eli Lilly Japan K.K. for Mounjaro, the world's first long-acting GIP/GLP-1 receptor agonist.」
The Japanese commercialization partnership for Mounjaro and the marketing approval obtained in September 2022 were reiterated as initiatives in the healthcare business for the fiscal year. - FY2023-Q2First statedAnnual report
「In July 2022, the company signed an agreement with Eli Lilly Japan K.K. (headquartered in Kobe, Hyogo Prefecture) to co-promote Mounjaro, the world's first long-acting GIP/GLP-1 receptor agonist, in Japan. Eli Lilly Japan obtained marketing approval in Japan for the product in September of the same year, with type 2 diabetes as its indication.」
田辺三菱製薬 entered into a Japanese commercialization partnership agreement with Eli Lilly Japan for Mounjaro, a long-acting GIP/GLP-1 receptor agonist, and progressed to obtaining Japanese marketing approval in September of the same year.